Complimentary overnight shipping & gift packaging on all ordersLearn More
Gifts for Her
Gifts for Him
Gifts by Occasion
Services
Customer Service
Shop by category
Bracelets
Earrings
Necklaces
Charms & Amulets
Rings
Watches
Material
Featured
Shop the Campaign
Pendants
Accessories
Collections
Featured Collections
Engagement
Wedding Bands
Crafted With Love
Discover
Stories
Sign up to receive email updates from David Yurman about the latest collections and news. You can unsubscribe at any time at no cost. By clicking Sign Up, you agree to our Privacy Policy and Terms of Use (including the class action waiver, the arbitration provisions, and all else in the dispute resolution section).
David Yurman is proud to partner with the Breast Cancer Research Foundation® for the 18th year, supporting its mission to prevent and cure breast cancer by advancing the world’s most promising breast cancer research. Discover iconic designs that help advance this lifesaving work.*
Charitable
Cable Collectibles® Ribbon Chain Bracelet 15mm
18K Rose Gold with Pavé
Cable Collectibles® Ribbon Chain Bracelet 1.5mm
Sterling Silver
Cable Collectibles® Ribbon Necklace 15.7mm
Cable Collectibles® Ribbon Necklace 24.4mm
To date, David Yurman has donated more than $3.5 million to the Breast Cancer Research Foundation®, helping advance breakthroughs in breast cancer prevention, diagnosis, treatment, survivorship, and metastasis.
The David Yurman Award for Breast Cancer Research is presented each year when annual donations reach $250,000 or more. Every contribution, no matter the amount, helps drive lifesaving discoveries.
Cable Collectibles® Ribbon Pin 18mm
Cable Collectibles® Pavé Plate Necklace 11mm
18K Rose Gold
Cable Bracelet 6mm
Pink Rubber
Cable Bracelet 10mm
Pavé Pinky Ring 10mm
Petite Pavé Pinky Ring 7mm
Meet two New York-based researchers whose work is advancing new approaches to breast cancer treatment: Dr. Hayley McDaid, who studies triple-negative and BRCA-driven breast cancers, and Dr. Sarat Chandarlapaty, a member of the BCRF Scientific Advisory Board who investigates why certain breast cancers become resistant to treatment. Below, they discuss their areas of research the new therapeutic approaches they’re developing to overcome treatment resistance.
DR. McDAID: Triple-negative breast cancer (TNBC) remains one of the most recalcitrant forms of breast cancer, particularly for patients who have inherited mutations in the BRCA1/2 genes. While drugs such as taxol are still effective for these patients, response rates are lower, and patients can become resistant to them, leading to relapse or metastasis. Research shows that after therapy, some breast cancer cells aren’t killed, but become dormant and may resume growth later. My lab is developing novel drugs that can induce cancer cell death particularly in TNBCs that no longer respond to drugs like taxol/paclitaxel. Another new benefit of these drugs is inducing a very stable form of dormancy that limits the ability of surviving tumor cells to grow back, or to metastasize. We are hopeful that this approach can help women with recalcitrant disease who need additional treatment choices.
DR. CHANDARLAPATY: We focus on two major types of breast cancer: those that have the receptor for the estrogen hormone, and those that have the HER2 receptor. Our lab is interested in understanding how these cancers evolve and develop resistance to anti-estrogens, CDK4/6 inhibitors, and anti-HER2 therapies, and then devising ways to combat these patterns of resistance. For instance, we found that breast cancers exposed to antiestrogen therapy develop mutations that cause the estrogen receptor to remain active, even without any estrogen. So we developed and studied drugs that can target those mutant estrogen receptors. At the same time, we’re studying the evolutionary process that allows breast tumors to develop resistance before it fully emerges. Our goal is to develop treatment strategies that can intervene earlier and potentially prevent resistance from developing in the first place.
The Breast Cancer Research Foundation is dedicated to preventing and curing breast cancer by advancing the world’s most promising research. This year, BCRF is the largest private funder of breast cancer research worldwide.
*Through July 31, 2027, David Yurman will donate to BCRF 100% of the net proceeds from the sale of each Pink Rubber Bracelet ($16.40 for online purchases or $24.30 for in-store purchases) and 20% of the retail sale price from select styles. Minimum guaranteed donation: $25,000.
Cookies are in use on this site
Discover new designs, personalized services, and style inspiration.
Unsubscribe at any time. By clicking Sign Up, you agree to our Privacy Policy and Terms of Use (including the class action waiver, the arbitration provisions, and all else in the dispute resolution section).
Thank you for signing up. You arenow subscribed.